Skip to Content

M2Bio Sciences Inc WUHN

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

M2Bio Sciences Inc, formerly Wuhan General Group (China) Inc is an alternative medicinal and botanicals company focused on the application of emerging technologies as well as the clinical research and health application of cannabidiol (CBD)-based medicine to the human and pet care industry for cancer, cardiovascular, mental disorders, chronic pain, and others in Canada, the United States, Europe, and Australia. It supplies medical grade CBD products, and superior patient care.

Contact
6500 Trans-Canada Highway, Suite 400
Montreal, QC, H9R 0A5
T +1 514 928-7368
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Dec 31, 2012
Fiscal Year End Dec 31, 2018
Stock Type Distressed
Employees 3